Literature DB >> 22686966

Transdermal nicotine during cue reactivity in adult smokers with and without anxiety disorders.

Sandra B Morissette1, Suzy Bird Gulliver, Barbara W Kamholz, David A Spiegel, Stephen T Tiffany, David H Barlow.   

Abstract

Transdermal nicotine almost doubles tobacco cessation rates; however, little is known about what happens to smokers during the quit process when they are wearing the nicotine patch and are confronted with high-risk smoking triggers. This is particularly important for smokers with psychological disorders who disproportionately represent today's smokers and have more trouble quitting. Using a mixed between- and within-subjects design, smokers with anxiety disorders (n=61) and smokers without any current Axis I disorders (n=38) received transdermal nicotine (21 mg) or a placebo patch over two assessment days separated by 48 hr. Urge to smoke was evaluated during a 5-hr patch absorption period (reflecting general smoking deprivation) and during imaginal exposure to theoretically high-risk triggers containing smoking cues, anxiety cues, both, or neutral cues. No differences were observed between smokers with and without anxiety disorders. Significant Patch×Time and Patch×Cue Content interactions were found. Both patch conditions experienced an increase in urge during the deprivation period, but postabsorption urge was significantly higher in the placebo condition, suggesting that transdermal nicotine attenuated the degree to which urge to smoke increased over time. During the cue reactivity trials, when participants received the nicotine patch, they experienced significantly lower urge in response to both smoking-only and neutral cues, but not when anxiety cues were present (alone or in combination with smoking cues). These data suggest that transdermal nicotine alleviates urge only under certain circumstances and that adjunctive interventions are likely necessary to address smoking urges in response to spikes in distress among smokers trying to quit. PsycINFO Database Record (c) 2012 APA, all rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22686966      PMCID: PMC3443526          DOI: 10.1037/a0028828

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  40 in total

1.  Effects of transdermal nicotine during imaginal exposure to anxiety and smoking cues in college smokers.

Authors:  Sandra Baker Morissette; Tibor P Palfai; Suzy Bird Gulliver; David A Spiegel; David H Barlow
Journal:  Psychol Addict Behav       Date:  2005-06

2.  Rapid absorption of nicotine from new nicotine gum formulations.

Authors:  Saul Shiffman; Edward J Cone; August R Buchhalter; Jack E Henningfield; Jeffrey M Rohay; Joe G Gitchell; John M Pinney; Tommy Chau
Journal:  Pharmacol Biochem Behav       Date:  2008-08-16       Impact factor: 3.533

3.  Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment.

Authors:  Jed E Rose; Joseph E Herskovic; Frederique M Behm; Eric C Westman
Journal:  Nicotine Tob Res       Date:  2009-06-30       Impact factor: 4.244

4.  Differences between smokers and nonsmokers with anxiety disorders.

Authors:  Sandra Baker Morissette; Timothy A Brown; Barbara Wolfsdorf Kamholz; Suzy Bird Gulliver
Journal:  J Anxiety Disord       Date:  2005-10-03

5.  Assessing DSM-IV nicotine withdrawal symptoms: a comparison and evaluation of five different scales.

Authors:  Robert West; Michael Ussher; Mari Evans; Mamun Rashid
Journal:  Psychopharmacology (Berl)       Date:  2005-11-25       Impact factor: 4.530

6.  Posttraumatic stress symptoms and smoking to reduce negative affect: an investigation of trauma-exposed daily smokers.

Authors:  Matthew T Feldner; Kimberly A Babson; Michael J Zvolensky; Anka A Vujanovic; Sarah F Lewis; Laura E Gibson; Candice M Monson; Amit Bernstein
Journal:  Addict Behav       Date:  2006-04-27       Impact factor: 3.913

Review 7.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

Review 8.  Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships.

Authors:  Sandra Baker Morissette; Matthew T Tull; Suzy Bird Gulliver; Barbara Wolfsdorf Kamholz; Rose T Zimering
Journal:  Psychol Bull       Date:  2007-03       Impact factor: 17.737

9.  High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking.

Authors:  Damaris J Rohsenow; Peter M Monti; Kent E Hutchison; Robert M Swift; Selene V MacKinnon; Alan D Sirota; Gary B Kaplan
Journal:  Exp Clin Psychopharmacol       Date:  2007-02       Impact factor: 3.157

10.  Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation.

Authors:  Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael F Fleming; Amy A Bittrich; Jennifer L Brown; Cathlyn J Leitzke; Mark E Zehner; Michael C Fiore; Timothy B Baker
Journal:  J Consult Clin Psychol       Date:  2010-02
View more
  4 in total

1.  Differences in Magnitude of Cue Reactivity Across Durations of Smoking History: A Meta-analysis.

Authors:  Joshua L Karelitz
Journal:  Nicotine Tob Res       Date:  2020-07-16       Impact factor: 4.244

2.  The effect of social anxiety on urge and craving among smokers with and without anxiety disorders.

Authors:  Nathan A Kimbrel; Sandra B Morissette; Suzy B Gulliver; Kirsten J Langdon; Michael J Zvolensky
Journal:  Drug Alcohol Depend       Date:  2013-11-13       Impact factor: 4.492

3.  Smoking cessation is associated with lower rates of mood/anxiety and alcohol use disorders.

Authors:  P A Cavazos-Rehg; N Breslau; D Hatsukami; M J Krauss; E L Spitznagel; R A Grucza; P Salyer; S M Hartz; L J Bierut
Journal:  Psychol Med       Date:  2014-09       Impact factor: 7.723

4.  Predicted Impact of Nicotine Reduction on Smokers with Affective Disorders.

Authors:  Diann E Gaalema; Mollie E Miller; Jennifer W Tidey
Journal:  Tob Regul Sci       Date:  2015-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.